What is QNCX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for QNCX?

P/E (TTM) is n/a and 52-week range is $15.10 to $910.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s QNCX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for QNCX?

The company profile lists net income (TTM) near $-123M, EPS (TTM) near $-125.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Quince Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 980K shares outstanding, ISIN US22053A2069 when available from company profile and filing metadata.

Quince Therapeutics Inc

$QNCX

Health Care · Biotechnology

IR Run Scenarios

$31.73

+8.07%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Quince Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 38 full-time employees. The company went IPO on 2019-05-09. Quince Therapeutics, Inc. is a late-stage biotechnology company. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

Employees

Website

quincetx.com/

IPO

2019-05-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)